Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DEX PS DDS · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| DEX PS DDS® | DRUG | - |
Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician. Exclusion: Females who are pregnant or lactating, and females of childbearing p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
DEX PS DDS is an investigational small molecule being studied for the treatment of diabetes and related retinal conditions, including macular edema, diabetic retinopathy, retinal disease, and posterior uveitis. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
DEX PS DDS is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is currently in Phase 2 clinical development for diabetes-related retinal conditions.
DEX PS DDS is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 2 clinical trial has been completed, and the drug remains under investigation for diabetes-related retinal conditions.
DEX PS DDS has one completed Phase 2 clinical trial registered under NCT00035906, titled "Research Study in Patients With Persistent Macular Edema." The trial enrolled 315 participants in the United States, including patients aged 12 years and older with diabetes, macular edema, diabetic retinopathy, retinal disease, and posterior uveitis.
No alternative names for DEX PS DDS have been disclosed. The drug is identified solely by its developmental name DEX PS DDS and is being studied by AbbVie Inc. for diabetes-related retinal conditions.
The specific molecular target or mechanism of action for DEX PS DDS has not been disclosed. As a small molecule in development for diabetes-related retinal conditions, its precise pharmacological action remains under investigation in clinical trials.